LIPIDS ADVANCES IN PRIMARY CARE: STRATEGY TOPICS PRACTICE-CHANGING PAPERS FROM THE PAST YEAR. Topics:
|
|
- Marjory Elliott
- 6 years ago
- Views:
Transcription
1 ADVANCES IN PRIMARY CARE: PRACTICE-CHANGING PAPERS FROM THE PAST YEAR Michael G. Shlipak, MD MPH Chief, Division of General Internal Medicine San Francisco VA Medical Center Professor In-Residence Departments of Medicine, Epidemiology & Biostatistics University of California, San Francisco STRATEGY Topics: Relevant to primary care Slanted towards cardiology/metabolism Goal: practice-modifying studies Mini-topics: Single papers in isolation often cannot tell a story I grouped paper from past year with other recent studies 2 TOPICS Lipids: simvastatin, fibrates, niacin, and HDL Treatment of stable angina: PCI, OMT, and cardiologists NSAIDs: do they all cause CAD? Hypertension: Diuretic choice, age, race CT scans: Is the radiation safe? LIPIDS Simvastatin, Fibrates, Niacin, and HDL 3 1
2 CASE STUDY An 80-year old white man with prior CAD and an LDL of 95 mg/dl is on 40 mg of simvastatin, but continues to have a low HDL of 24 mg/dl. Should you add niacin to his treatment regimen to raise his HDL? Should you raise his simvastatin or change treatment? TREATMENTS TO INCREASE HDL Niacin Raises HDL by 20% Fibrates (Gemfibrozil, Bezafibrate) Raises HDL by 15-30% CETP inhibitors (Torcetratib) Raises HDL by 72% Unfortunately, it increases mortality (NEJM, 2007) Do any improve outcomes? 5 6 AIM-HIGH STUDY: ATHEROTHROMBOSIS INTERVENTION IN METABOLICSYNDROME WITH LOW HDL/HIGH TRIGLYCERIDES: IMPACT ON GLOBAL HEALTH Participants: N=3,414 in US and Canada Inclusion criteria: Prior CVD On a statin Low HDL and high TG Design: Placebo-controlled RCT Intervention: Niaspan 2 g/day or placebo Outcomes: CVD death, MI, CVA, ACS, revascularization 7 Follow-up: 36 months AIM-HIGH Investigators, NEJM 2011 AIM-HIGH STUDY Participants: Average age: 64 Hypertension: 71% Diabetes Mellitus: 34% Prior Myocardial Infarction: ~50% Coronary Artery Disease: 92% 8 AIM-HIGH Investigators, NEJM
3 AIM-HIGH FINDINGS CASE STUDY CONTINUED Trial stopped early Event rate was same in both groups Small increase in stroke risk on niacin reported in press 27 strokes (1.6%) with niacin versus 15 (0.9%) with placebo HR 1.61, 95% CI Not statistically significant (p=0.11) Answer: no benefit to adding niacin for statintreated patients 9 An 80-year old white man with prior CAD and an LDL of 95 mg/dl is on 40 mg of simvastatin, but continues to have a low HDL of 24 mg/dl. Should you add niacin to his treatment regimen to raise his HDL? Should you raise his simvastatin or change treatment? 10 AIM-HIGH Investigators, NEJM 2011 FDA RESTRICTS USE OF SIMVASTATIN June 8, 2011: FDA restricts use of 80mg simvastatin because of increased risk of myopathy FDA recommends: No new patients on simvastatin 80mg Okay to maintain patients on 80mg if >1 year without symptoms of muscle toxicity Beware of drug interactions Was this an over-reaction? Is simvastatin different from other statins? 11 SEARCH TRIAL: STUDY OF THE EFFECTIVENESS OF ADDITIONAL REDUCTIONS IN CHOLESTEROL AND HOMOCYSTEINE Funded by Merck 7-year RCT comparing: Simvastatin 80mg vs. 20mg Subjects: 12,064 patients with prior MI Outcome: major vascular events (coronary death, MI, stroke, arterial revascularization) Results: no difference (RR 0.94, 95%CI ) 12 SEARCH Study Group The Lancet,
4 SEARCH TRIAL RESULTS NEW LABEL ON SIMVASTATIN Difference in myopathy risk: Myopathy (muscle weakness + CK >10x ULN) 80 mg: 52 patients (0.9%) 20 mg: 1 patient (0.02%) Rhabdomyolysis (muscle weakness + CK>40x ULN) 80 mg: 22 patients (0.4%) 20 mg: 0 patients Risk 5-fold higher in year 1 compared with subsequent years Key drug interactions noted 13 Simvastatin contraindicated in users of: Antifungals Macrolide antibiotics Antiretrovirals Gemfibrozil Do not exceed 10mg simvastatin if using: Verapamil Diltiazem Calcium channel blockers are very common in primary care Do not exceed 20mg simvastatin with: Amlodipine Ranolazine Amiodarone 14 SEARCH Study Group The Lancet, 2010 FDA Safety Announcement, 6/8/2011 LDL-LOWERING EFFECTS OF SIMVASTATIN Simvastatin % Lowered LDL-C 10 mg 30% 20 mg 38% 40 mg 41% 80 mg 47% 15 WHAT SHOULD WE DO? Myopathy risks appear higher with simvastatin compared with other statins Don t go beyond 20 mg, unless you have a good pharmacy or great memory Simvastatin 20 mg equivalent to: Prava 40 mg Lova mg If simvastatin 20 mg gives inadequate LDL, use atorvastatin or rosuvastatin 16 FDA Safety Announcement, 6/8/2011 4
5 CASE STUDY FOLLOW-UP You decide your patient should switch to atorvastatin. However, he has now stopped his statin due to adverse publicity and will not restart. You recheck his lipids; his HDL is 24 mg/dl and his LDL is 130 mg/dl. For non-statin-treated patients, should you treat HDL? If so, which of the following would be appropriate? Fibrate What if the patient cannot or will not take a statin? Niacin NIACIN META-ANALYSIS OF PLACEBO- CONTROLLED RCTS SUMMARY OF RESULTS FOR CARDIOVASCULAR EVENTS Summary of 11 RCTs Coronary Drug Project (from the 1970s): only large-scale RCT Other studies very small 27% lower risk of CVD events Publication bias?? Bruckert et al. Atherosclerosis 2010 Bruckert et al. Atherosclerosis
6 FIBRATE META-ANALYSES Do fibrates improve clinical outcomes? 4 fibrate meta-analyses in past year Lee et al. Atherosclerosis 2011 Bruckert et al. J Cardiovasc Pharmacol 2011 Loomba and Arora Am J Ther 2010 Jun et al. The Lancet EFFECTS OF FIBRATES ON CARDIOVASCULAR OUTCOMES Design: systematic review and meta-analysis Analysis: 18 RCTs from Participants: N=45,058 FIBRATE VS. PLACEBO AND CVD RISK Outcome Relative Risk 95% CI P Value Non-fatal coronary events < Total stroke Cardiovascular death All-cause mortality Jun et al. The Lancet 2010 Jun et al. The Lancet
7 DATA SUMMARY For patients with low HDL: Statins are treatment of choice to decrease CVD risk, regardless of LDL No data to add either niacin or fibrates to statin treatment (AIM-HIGH, ACCORD trials) If statin-intolerant, niacin may reduce CVD risk (weak evidence) Fibrates appear to lower MI risk, but no other CVD endpoints TREATMENT OF STABLE ANGINA PCI, OMT, and Cardiologists CASE STUDY Your patient returns. He has chest pain that he describes as similar to the angina he had in the past. Onset after 2 blocks of walking, and resolves quickly with rest. As his primary care provider, you counsel him that optimal medical therapy (OMT) is the standard of care for chronic, stable angina. The patient is skeptical and requests a specialist, so you refer him to a cardiologist. CASE STUDY FOLLOW-UP The patient returns to your office 8 weeks later for a follow-up visit after having received a stent. What happened? Will the stent help the patient?
8 CAD AND INTERVENTIONS COURAGE TRIAL Optimal medical therapy (OMT) Antiplatelet agent, β-blocker, Statin Unless contraindicated Prior to stent era, in chronic stable angina, statins had better outcomes than angioplasty (Pitt et al. NEJM 1999) Currently, 85% of all percutaneous coronary intervention (PCI) procedures are elective in patients with stable angina 29 Conducted to compare OMT with and without PCI N=2,287 patients with stable angina and ischemia, ,149 had PCI + OMT 1,138 had OMT alone Funded by the US VA R&D/Canadian Institutes of Health Research Outcome: All-cause mortality Non-fatal MI Average follow-up: 4.6 years 30 Boden et al. NEJM 2007 COURAGE OUTCOMES COURAGE RESULTS Adverse event rates: 19.0% in PCI group 18.5% in OMT group HR PCI vs. no PCI: RR Composite death/mi/stroke: 1.05, Hospitalization for ACS: 1.07, Myocardial Infarction: 1.13, PCI doesn t reduce risk of death, MI, or other CV events when added to OMT in patients with stable angina 32 Boden et al. NEJM 2007 Boden et al. NEJM
9 COURAGE AFTERMATH Huge amount of news coverage Lots of controversy This should have changed practice, right? OMT USE IN PATIENTS UNDERGOING PCI Examined use of OMT in pts. with stable angina undergoing PCI before and after COURAGE trial publication Design: Observational Setting: National Cardiovascular Data Registry, Borden et al. JAMA 2011 OMT USE BEFORE AND AFTER PCI, BY ERA OMT USE BEFORE AND AFTER PCI, BY ERA Number (%) of Patients Before PCI After PCI Individual Medications Before COURAGE (n=173,416) After COURAGE (n=293,795) Antiplatelet Agent β-blocker Statin OMT Pre- PCI OMT Post-PCI Borden et al. JAMA 2011 Borden et al. JAMA
10 CONCLUSIONS The responsibility of administering the full complement of medical therapy, however, ought not to be placed solely on the interventional cardiologist, but rather be a shared responsibility with the primary physicians caring for the patient. Borden et al. JAMA 2011 What are cardiologists thinking? Borden et al. JAMA 2011 CARDIOLOGISTS USE OF PCI FOR STABLE CAD Design: focus groups of cardiologists in N. Cal Research Question: Why do cardiologists ignore COURAGE results? Reasons given for performing PCI in stable angina: Belief in the benefits of treating ischemia Belief in the open artery hypothesis Potential regret (psychological and legal) for not intervening if a cardiac event could be averted Alleviation of patient anxiety Oculostenotic reflex Belief that referring PCP expects a procedure 39 CONCLUSIONS We need to fully implement OMT (β-blocker, statin, aspirin) first, before referring to cardiologists We need to resist the urge to fix patients angina by stenting We need to educate patients that stents do not help in the long run We need to be clear about our expectations prior to referring patients to cardiologists 40 Lin et al. Arch Intern Med
11 CASE STUDY NSAIDS Do they all cause CAD? Now that your patient with stable CAD is on OMT, he has increased exercise, as you recommended. However, he has developed persistent knee pain and wants to take prescription-strength ibuprofen. The label says to ask a doctor before use if you have heart disease. Is the risk real? 42 NSAIDS AND CV RISK Non-steroidal anti-inflammatory drugs (NSAIDs) among most commonly used drugs 2004: rofecoxib (Vioxx) withdrawn from market after RCT showed very strong evidence promoting MI risk Since then, concern and debate over safety of NSAIDs Several standard meta-analyses unable to resolve debate failed to integrate all evidence in one analysis Do non-selective NSAIDS promote CV risk? 43 CV SAFETY OF NSAIDS Meta-analysis: 31 RCTs in 116,429 patients with >115,000 patient years of follow-up Subjects: mostly low CAD risk Analysis: network meta-analysis Primary outcome: Myocardial Infarctions Secondary outcomes: stroke, CV death, allcause mortality 44 Trelle et al. BMJ
12 NETWORK ANALYSES RATE RATIOS FOR NSAIDS COMPARED WITH PLACEBO 676 deaths 1,091 CVD events Average 22 deaths, 35 CVD events per study Trelle et al. BMJ 2011 Trelle et al. BMJ 2011 CONCLUSIONS Study confirms that NSAIDs are associated with increased CVD event risk Naproxen seems to be safest Most subjects had low CV risk What about patients with high CAD risk? DURATION OF NSAID TREATMENT AND RISK OF MI Design: Observational Location: Denmark Participants: N=83,677 with first MI from % used NSAIDs during F/U Outcomes: death, recurrent MI N = 35, Trelle et al. BMJ 2011 Schjerning Olsen et al. Circulation
13 RISK OF DEATH/RE-MIS WITH NSAID TREATMENT CONCLUSIONS MI risk from NSAIDS appears real NSAIDS should be used only short-term in CAD patients American Geriatric Society recommended therapies include: Tylenol, exercise, topical NSAIDs, opiates NSAID CV risk RR of 1.5; in context: 4% 3% Statins 30% 49 2% 1% NSAIDs 50% 50 Schjerning Olsen et al. Circulation % CV Risk Schjerning Olsen et al. Circulation 2011 CASE STUDY HYPERTENSION Diuretic Choice, Age, Race The wife of your patient is an 80 year old African American woman with hypertension. Her SBP is consistently According to JNC-VII (2003), HCTZ is an ideal first-line treatment. However: Is HCTZ the best diuretic to choose? Should BP targets be different for the elderly? Should BP targets be different for blacks? 52 13
14 HYPERTENSION GUIDELINES BP treatment guidelines haven t been updated, but lots of new data in last 8 years 3 recent guidelines/expert opinions: European Hypertension Guidelines (2011) ACC/AHA Elderly (2011) International Society on Hypertension in Blacks (2010) JNC-VIII expected in Spring 2012 IS HCTZ AN INFERIOR DIURETIC? Hydrochlorothiazide (HCTZ): most commonly prescribed thiazide in US Meta-analysis compared HCTZ with nondiuretics using office and 24-hr BP N=1,463 patients in 19 studies Messerli et al. JACC 2011 HCTZ WEAKER EFFECTS BY 24-HR BP MONITORING HCTZ equivalent with other agents by office BP IS CHLORTHALIDONE BETTER THAN HCTZ? Design: Meta-analysis of 108 HCTZ clinical trials and 29 Clorthalidone (CLD) clinical trials Objective: Compared dose-response curves of HCTZ and CLD with changes in SBP and potassium Messerli et al. JACC 2011 Ernst et al. Am J of Hypertension
15 CLORTHALIDONE IS MORE POTENT THAN HCTZ Drug Mean SBP, mmhg Mean Potassium, meq/l CLD DIURETIC CONCLUSIONS CLD is the more potent diuretic, probably because of its longer half-life Most RCTs that found diuretics to decrease CV risk have used CLD 2011 European guidelines advise using CLD or indapamide, not HCTZ HCTZ Ernst et al. Am J of Hypertension 2010 SHOULD SBP TARGET DIFFER IN ELDERLY (>80)? Current JNC-VII treatment target <140/90 in all age groups is based on expert opinion rather than RCTs Ideal target in elderly (>80) unclear HYVET Trial showed target <150 had better outcomes than >160 (NEJM 2008) 2011 AHA recs in elderly: is acceptable, if tolerated 2011 European recs for >80: <150/90 is acceptable Both documents recommend caution in treating elderly to balance QoL with prevention goals 59 MANAGEMENT OF HTN IN BLACKS Expert panel recommends more aggressive BP treatment targets Primary prevention: <135/85 Broad list of high risk groups should have <130/80 target Best 2-drug combos: Ca channel blocker + ACE-ARB ACE-ARB + diuretic Recommend using ambulatory BP measures for decision-making 60 Flack et al. Hypertension
16 CASE STUDY CT SCANS Is the Radiation Safe? Your patient and his wife return for a visit. Both are doing well, and are interested in cancer screening. They read a news report about using CT scans to determine lung cancer. As former smokers, they ask your opinion on CT scans as screening tests. Should you be concerned about radiation risks? 62 ARE CT SCANS SAFE Topic receiving lots of attention Especially relevant for strategies using CT to screen for CAD or lung cancer Number of CTs performed annually in US went from 3 to 70 million from RADIATION AND CANCER Biological Effects of Ionizing Radiation (BEIR) VII Phase 2 Report (2006): Described survivors from atomic bombs and nuclear plant accidents Hiroshima/Nagasaki bomb survivors who received msv exposures have increased risk of cancer A single modern CT scan can have equivalent radiation exposure Smith-Bindman NEJM 2010; Miglioretti and Smith-Bindman Am Fam Phys
17 VARIABILITY IN RADIATION DOSE AND CANCER RISK Setting: 4 N. Cal hospitals Participants: 1,119 consecutive adult patients, Jan-May 2008 Exposure: effective radiation dose to relevant organs Outcome: projected impact on cancer risk DISTRIBUTION OF ESTIMATED EFFECTIVE DOSE BY CT TYPE Minimum thresholds for specific cancers in atomic bomb studies 65 Smith-Bindman et al. Arch Intern Med 2009 Smith-Bindman et al. Arch Intern Med 2009 PROJECTED NUMBER OF CTS TO CAUSE 1 CANCER Type of CT Study Patients (Age 40y), Median (IQ Range), No. Female Male Routine chest, no contrast 720 ( ) 1566 ( ) Coronary angiogram 270 ( ) 595 ( ) 67 Smith-Bindman et al. Arch Intern Med 2009 IMPLICATIONS IN CURRENT PRACTICE CT-machine manufacturers compete on basis of image quality directly associated with radiation dose Increased imaging speed also leads to higher doses No professional/governmental oversight Radiologists/medical specialists determine how CT tests performed Physicians know little about radiation doses/cancer risks from CTs CT techs don t receive consistent education 68 many not certified Smith-Bindman NEJM 2010; Miglioretti and Smith-Bindman Am Fam Phys
18 HOPE FOR FUTURE FDA launched radiation initiative in Feb Encourages professional organizations to take the lead in setting reference levels Safety experts recommend following goals: 50% lower doses for scans Standardized to low radiation default dosing Reduce number of CT scans performed THANK YOU! 69 ANY QUESTIONS? 70 18
FEATURES OF THIS TALK
FEATURES OF THIS TALK OUTPATIENT MANAGEMENT OF CAD- A PRIMARY CARE PERSPECTIVE Michael G. Shlipak, MD, MPH Professor of Medicine, Biostatistics, and Epidemiology Chief, General Internal Medicine Covers
More information7/27/2017 DISCLOSURES OUTPATIENT MANAGEMENT QUESTION #1 FEATURES OF THIS TALK OF CAD- A PRIMARY CARE PERSPECTIVE
DISCLOSURES OUTPATIENT MANAGEMENT OF CAD- A PRIMARY CARE PERSPECTIVE I am on the Scientific Advisory Boards with stock option compensation for the following companies: TAI Diagnostics Cricket Health, Inc.
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More information2/17/2010. Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco
Modern Management of Patients with Stable Coronary Artery Disease Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco Scope of the Problem Prevalence of CAD: 17.6 million
More informationUpdate in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP
Update in Cardiology Pharmacologic Management of Cardiovascular Risk Christopher C. Roe, MSN, ACNP Objectives 1. Verbalize understanding of new pharmacologic guidelines in the treatment of hypertension
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationThe Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4)
The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4) Denis Xavier MD, MSc Professor and Head, Pharmacology, St. John's Medical College Coordinator, Division
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationStatin Intolerance. Jason Evanchan DO, FACC April 20 th, 2018
Statin Intolerance 2 nd Annual CV Course for Trainees and Early Career Physicians: Current Concepts in the Diagnosis and Management of Coronary Artery Disease Jason Evanchan DO, FACC April 20 th, 2018
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationHyperlipidemia. Intern Immersion Block 2015
Hyperlipidemia Intern Immersion Block 2015 Christopher Wong, MD Division of General Internal Medicine University of Washington cjwong@u.washington.edu Welcome! Disclosures: royalties from book sales (not
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationAdvances in Cardiovascular Diagnosis and Therapy. No disclosure or conflicts. Outline
Advances in Cardiovascular Diagnosis and Therapy Firas Zahr, MD Assistant Professor of Medicine Interventional Cardiology University Of Iowa No disclosure or conflicts Outline What is new with revascularization?
More information5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016
Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss
More informationDisclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationOutline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationPrevention of Heart Disease: The New Guidelines
Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015
More informationScreening for Lung Cancer: U.S. Preventive Services Task Force Recommendation. Hot Off the Press and into Your Practice: The Last Year in Medical News
Hot Off the Press and into Your Practice: The Last Year in Medical News Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Moyer VA, et al. Ann Internal Med. 2014;160(5):330-338.
More informationDoes High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi
More informationUpdates in Cardiovascular Recommendations for Diabetic Patients
Updates in Cardiovascular Recommendations for Diabetic Patients Chris Tawwater, Pharm.D., BCPS Clinical Pharmacist, Abilene Regional Medical Center Assistant Professor, Adult Medicine Division Pharmacotherapy
More informationClinical Controversies in Perioperative Medicine
Clinical Controversies in Perioperative Medicine Hugo Quinny Cheng, MD Division of Hospital Medicine University of California, San Francisco Cardiac Evaluation: New Guidelines A 70-y.o. man with progressive
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationRoyal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease
Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines 1 This guideline is intended to assist rational and cost-effective prescribing of lipid regulating medications across both primary and
More informationBest Practices in Cardiac Care: Getting with the Guidelines
Best Practices in Cardiac Care: Getting with the Guidelines December 9, 2014 Agenda Cardiovascular Disease: How do the guidelines fit into an implementation scheme? What the guidelines set out to accomplish
More informationTreatment Options for Angina
Treatment Options for Angina Interventional Cardiology Perspective Michael A. Robertson, M.D. 10/30/10 Prevalence of CAD in USA 15 million Americans with CAD 2 million diagnostic catheterizations 1 million
More information4/24/15. AHA/ACC 2013 Guideline Key Points
Review of the ACC/AHA 2013 Guidelines Anita Ralstin, MS, CNS, CNP Next Step Health Consultant, LLC 1! Discuss the rationale for the change in lipid guidelines and how that affects the decision to implement
More informationControversies in Preventative Cardiology
Controversies in Preventative Cardiology Francisco Lopez-Jimenez, M.D., M.Sc, FACC, FAHA Professor of Medicine, Mayo Medical School Chair, Division of Preventive Cardiology Co-Director, Artificial Intelligence
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationHypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016
Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationDisclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.
Disclosures Prevention of Heart Disease: The New Guidelines No relevant disclosures Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California
More informationDisclosures. Choosing a Statin/New Therapies. Case. How else would you do to treat him? LDL-C Reduction with Different Statin Strategies
Disclosures I have no disclosures relevant to this talk Choosing a Statin/New Therapies Aryan Aiyer, MD Assistant Professor of Medicine University of Pittsburgh School of Medicine UPMC Heart and Vascular
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More information2/10/2016. Perspectives on the 2013 ACC/AHA Cholesterol Guidelines. Disclosures. ATP-III Update 2004
Perspectives on the 2013 ACC/AHA Cholesterol Guidelines Donald M. Lloyd-Jones, MD ScM Senior Associate Dean Chair and Professor of Preventive Medicine Northwestern Feinberg School of Medicine Disclosures
More informationHYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS
HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS Michael J. Scalese, PharmD, BCPS, CACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 14, 2018 DISCLOSURE/CONFLICT OF INTEREST
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationClinical Practice Guideline
Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationBlood Pressure LIMBO How Low To Go?
Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationJuly 2011 Medical Update Information
July 2011 Medical Update Information Simvastatin (Zocor) new FDA restrictions FDA statement June 2011 Based on the SEARCH 7 year trial in patients who were considered stable after have had a heart attack.
More informationThe Cardiovascular Institute Mount Sinai School of Medicine, New York
The Cardiovascular Institute Mount Sinai School of Medicine, New York HDL YES HDL NO Juan Jose Badimon, Ph.D Professor of Medicine Director, Atherothrombosis Research Unit The Mount Sinai School of Medicine
More informationOutline. Introduction. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 6/26/2012
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More information2017 Cardiovascular Summit for Primary Care Thursday 30th & Friday 31st March Crowne Plaza, Dublin
2017 Cardiovascular Summit for Primary Care Thursday 30th & Friday 31st March 2017 - Crowne Plaza, Dublin 2016 ESC Guidelines on Cardiovascular Risk and elevated lipids Carlos Brotons Sardenya Primary
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationClinical cases with Coversyl 10 mg
Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationStatins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More information